335 related articles for article (PubMed ID: 11010621)
1. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Jan; 65(4):1000-50. PubMed ID: 11010621
[TBL] [Abstract][Full Text] [Related]
2. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body; partial stay of compliance. Food and Drug Administration, HHS. Final rule; partial stay of compliance.
Fed Regist; 2000 Sep; 65(190):58346-50. PubMed ID: 11503646
[TBL] [Abstract][Full Text] [Related]
3. Food labeling: health claims and labeling statements; dietary fiber and cancer; antioxidant vitamins and cancer; omega-3 fatty acids and coronary heart disease; folate and neural tube defects; revocation. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Oct; 65(192):58917-8. PubMed ID: 11503652
[TBL] [Abstract][Full Text] [Related]
4. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
[TBL] [Abstract][Full Text] [Related]
5. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
Food and Drug Administration, HHS
Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
[TBL] [Abstract][Full Text] [Related]
6. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
[TBL] [Abstract][Full Text] [Related]
7. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final rule for over-the-counter antitussive drug products; technical amendment. Final rule, technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2007 Nov; 72(230):67639-40. PubMed ID: 18064767
[TBL] [Abstract][Full Text] [Related]
8. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
[TBL] [Abstract][Full Text] [Related]
9. Health-benefit claims for probiotic products.
Heimbach JT
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S122-4; discussion S144-51. PubMed ID: 18181716
[TBL] [Abstract][Full Text] [Related]
10. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
[TBL] [Abstract][Full Text] [Related]
11. What makes consumers think dietary supplements are safe and effective? The role of disclaimers and FDA approval.
Dodge T; Kaufman A
Health Psychol; 2007 Jul; 26(4):513-7. PubMed ID: 17605572
[TBL] [Abstract][Full Text] [Related]
12. Structure/function claims in dietary supplement labeling: not all of these claims need to be submitted to FDA and accompanied in labeling by the DSHEA disclaimer.
McNamara SH
Food Drug Law J; 1999; 54(1):35-42. PubMed ID: 11758558
[No Abstract] [Full Text] [Related]
13. Food labeling: health claims; omega-3 fatty acids and the risk in adults of cardiovascular disease--FDA. Interim final rule.
Fed Regist; 1998 Jun; 63(119):34107-10. PubMed ID: 10180289
[TBL] [Abstract][Full Text] [Related]
14. Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.
Fed Regist; 1999 Aug; 64(158):44653-8. PubMed ID: 10558603
[TBL] [Abstract][Full Text] [Related]
15. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States?
Gibson JE; Taylor DA
J Pharmacol Exp Ther; 2005 Sep; 314(3):939-44. PubMed ID: 15833895
[TBL] [Abstract][Full Text] [Related]
16. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Feb; 69(28):6787-854. PubMed ID: 14968803
[TBL] [Abstract][Full Text] [Related]
17. Drug labeling; orally ingested over-the-counter drug products containing calcium, magnesium, and potassium. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Mar; 69(57):13725-35. PubMed ID: 15040351
[TBL] [Abstract][Full Text] [Related]
18. Pediculicide drug products for over-the-counter human use; amendment of final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(250):75414-8. PubMed ID: 14986677
[TBL] [Abstract][Full Text] [Related]
19. Food labeling: health claims; chromium and the risk in adults of hyperglycemia and the effects of glucose intolerance--FDA. Interim final rule.
Fed Regist; 1998 Jun; 63(119):34104-7. PubMed ID: 10180288
[TBL] [Abstract][Full Text] [Related]
20. Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
Seamon MJ; Clauson KA
J Herb Pharmacother; 2005; 5(3):67-86. PubMed ID: 16520299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
